Symphytum officinale 6c homeopathic tablets
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 5 · Randomised trials: 6 · 1978–2026
Showing the 50 most relevant studies, sorted by most relevant.
Claudia-Crina Toma, Mariangela Marrelli, Monica Puticiu, et al.
Plants, 2024
Sosie Kassab, Mike Cummings, Saul Berkovitz, et al.
Cochrane Database of Systematic Reviews, 2009
- Antineoplastic Agents
- Breast Neoplasms
- Homeopathy
Catharine Avila, Ian Breakspear, Jason Hawrelak, et al.
Fitoterapia, 2020
Robbert van Haselen, Peter Fisher
Lara D. Veeken, 2000
- Homeopathy
- Administration, Topical
- Anti-Inflammatory Agents, Non-Steroidal
Liu X, Huang X, Song X
2026
Symphytum officinale: L. (S. officinale), commonly known as comfrey, has been used in traditional medicine for over 2,000 years to treat wounds, fractures, and inflammatory conditions. This review is the first comprehensive ethnopharmacological synthesis that systematically integrates cross-cultural traditional knowledge with the latest evidence on its phytochemical profile, pharmacological mechanisms, clinical efficacy, and toxicological risks. Unlike previous fragmented reviews that addressed only isolated aspects, we followed PRISMA guidelines to analyze selected studies, with a strong emphasis on developing safe, pyrrolizidine alkaloid (PA)-depleted topical formulations that translate the plant's classic "knitbone" reputation into modern evidence-based phytotherapy. Key bioactive constituents-allantoin, rosmarinic acid, polysaccharides, and lignans-exert anti-inflammatory, tissue-regenerative, and bone-repair effects primarily by inhibiting NF-κB and MAPK pathways and suppressing pro-inflammatory cytokines. Randomized controlled trials demonstrate that topical S. officinale preparations significantly outperform placebo in acute back pain, knee osteoarthritis, ankle sprains, and myalgia, while showing non-inferiority to diclofenac and an excellent safety profile. However, the presence of hepatotoxic PAs (intermedine and lycopsamine) strictly limits internal use. Topical application remains safe owing to minimal systemic absorption. By bridging historical wisdom with rigorous contemporary data and spotlighting PA-depletion strategies, this review offers a balanced framework for safe clinical application and future formulation optimization.
Abstract licence: CC BY 4.0
Kristiyan Stefanov, Dragomir Vassilev
INTERNATIONAL SCIENTIFIC CONFERENCE - UNITECH, 2025
Bahare Salehi, Farukh Sharopov, Tugba Boyunegmez Tumer, et al.
Molecules, 2019
- Anti-Infective Agents
- Antioxidants
- Food Preservation
Beatriz Bertolaccini Martínez, Elisa Coutinho Moura
INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH, 2021
Shilun Chen, H. Shang, Junyan Yang, et al.
Industrial Crops and Products, 2018
Aphale P, Shekhar H, Dokania S
2025
- Materia Medica
- Homeopathy
- Biomedical Research
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.